Semaglutide vs. Tirzepatide: What the Trials Show

These are the two molecules the entire GLP-1 market runs on. They are related but not identical, and the trial evidence for each is specific enough that you can compare them on the numbers instead of the marketing. Here is what the studies actually report — and what that does and does not mean for a decision.

Different receptors, different design

Semaglutide is a GLP-1 receptor agonist: it acts on a single incretin pathway to blunt appetite and slow gastric emptying. Tirzepatide is a dual agonist, acting on both the GIP and GLP-1 receptors. That mechanistic difference is the leading hypothesis for why tirzepatide has posted larger average weight reductions in its trials — though "larger on average" is a statement about study populations, not a promise for any individual.

The weight-loss numbers, side by side

For semaglutide, the pivotal STEP-1 trial tested once-weekly semaglutide 2.4 mg in adults with overweight or obesity and reported a mean body-weight change of about −14.9%, versus roughly −2.4% for placebo, at 68 weeks¹. The approved dosing and titration schedule are laid out in the Wegovy prescribing information².

For tirzepatide, the SURMOUNT-1 trial ran 72 weeks and reported mean reductions of roughly −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg³. Read across, the higher tirzepatide doses produced larger average weight loss than semaglutide did in its trial — but note these are separate studies with different designs, so the cleanest comparison comes from a head-to-head. Those same trials also show a wide spread of individual results around each average — see why GLP-1 weight loss varies so much from person to person for the categorical breakdown behind the headline numbers. And if you're weighing tirzepatide specifically, the brand question runs one layer deeper than semaglutide's — see Mounjaro vs. Zepbound.

The one head-to-head trial

SURPASS-2 compared tirzepatide directly against semaglutide 1 mg once weekly in adults with type 2 diabetes. Tirzepatide produced greater reductions in both A1c and body weight than semaglutide across its dose range⁴. Two caveats keep this honest: SURPASS-2 studied a diabetes population, not a general weight-management one, and it used the 1 mg diabetes dose of semaglutide rather than the 2.4 mg weight-management dose. It is the best direct comparison available — and still not a perfect stand-in for the weight-loss question.

Side effects and tolerability

Both molecules share the GLP-1 side-effect profile: nausea, diarrhea, constipation, and vomiting are the common ones, generally worst during dose escalation and easing as the body adjusts. Both carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, as the Wegovy labeling details for semaglutide². Tolerability is individual: the drug with the better average numbers is not automatically the one your body tolerates better — our full side-effects review covers the complete risk profile for both molecules, including the rarer signals beyond nausea. If a compounded oral or sublingual version of either drug is on the table, what the absorption science actually requires is worth reading before you assume it works the same as an injection.

So which one?

The trials favor tirzepatide on average weight loss, and the single head-to-head favors it on both weight and glucose in a diabetes population. But "better in the aggregate" is not "better for you." The molecule you can actually access, afford at your maintenance dose, and tolerate week to week beats a slightly higher trial average you never reach — and because weight tends to return after stopping, "afford at your maintenance dose" means for the long haul, not just month one. Check how a provider prices the ladder rather than the first rung — Pepti advertises one flat price at every titration dose, which is a strong claim worth getting in writing, since its own production data carries a per-dose ladder that contradicts it. Decide the drug and the provider together — our six-point checklist covers the provider side, and what compounded GLP-1 costs per month covers the money.

Bring it to a prescriber

This is a starting point for a conversation, not a substitute for one. A licensed clinician who knows your history should make the call on molecule, dose, and monitoring. To see which providers offer both molecules with a full titration ladder, browse our reviews and comparisons. If tirzepatide is the one you land on, the graded tirzepatide ranking shows each provider's score broken into its six weighted parts, and how the WeighScore is calculated explains what each part is worth.